Responsibility does not end at the dispensing pharmacy. On March 3, 2026, FDA announced 30 telehealth warning letters addressing misleading compounded-GLP-1 claims. Its examples included implying equivalence with approved drugs and obscuring the actual compounder through unqualified telehealth branding. FDA announcement. (fda.gov)
The FTC’s November amended Hims & Hers complaint adds a separate procurement concern: allegations involving disclosure of sensitive health information to advertising platforms and deceptive billing/cancellation practices. These allegations should not be presented as proven violations. FTC release. (ftc.gov)
Recommended vendor test:
- Inventory advertising tags and data recipients across intake, payment and account pages.
- Identify who can change approved-drug, compounded-drug and sourcing claims.
- Test when a patient is charged relative to clinical review.
- Walk through cancellation, refunds and outstanding prescriptions.
- Require approval before a partner changes the dispensing entity, product presentation or patient-facing claims.
These are recommended controls, not a claim that the litigation created a new universal compliance deadline.
Sources cited on this page
- fda.gov · Source 1 ↗https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s
- ftc.gov · Source 2 ↗https://www.ftc.gov/news-events/news/press-releases/2026/11/five-states-join-ftc-lawsuit-alleging-hims-hers-engaged-deceptive-unlawful-privacy-practices
- ftc.gov · Source 3 ↗https://www.ftc.gov/news-events/news/press-releases/2026/11/five-states-join-ftc-lawsuit-alleging-hims-hers-engaged-deceptive-unlawful-privacy-practices?utm_source=openai